NSNicholas H. Stillman

Nicholas H. Stillman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicholas H. Stillman has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthesis of Large‐ and Medium‐Sized Heterobiaryl Atropisomeric Rings and Atropopeptides by Catalytic Intramolecular S N Ar

    by Alireza Abbasi Kejani, Paritosh Dey, Nicholas H. Stillman, Daniel M. Andrade, Michal Šimek, Martin Dračínský, Daniel Bím, Paulo H. S. Paioti

    We report the first examples of catalytic, intramolecular N‐heterocycle arylation by nucleophilic aromatic substitution (S N Ar), a general method for synthesis of highly strained macrocycles and medium‐sized heterobiaryl atropisomeric rings. Key to the approach is the ability to generate a strong base catalytically, as the desired cyclizations can be problematic under non‐catalytic conditions. Substitution reactions catalyzed by Brønsted bases often suffer from poor turnover because leaving groups are poorly basic. We put forth a process in which base regeneration does not depend on p K a considerations, but on reaction of a fluoride catalyst (Lewis base) with an organosilane (base‐embedding electrophile). Our protocol is amenable to an unprecedented broad range of heterocycles and highly functionalized and sterically hindered fluoroarenes. Despite ring strain, direct formation of C─N stereogenic axis can be carried out with linear substrates unbiased for cyclization and with tryptophan‐containing peptides. We provide synthesis of drug‐like cyclic and atropisomeric molecules which are elusive in medicinal chemistry screenings, as well as a direct macrocyclization route toward stereochemically and structurally diverse atropopeptides, molecules inspired by bioactive and naturally occurring ribosomally synthesized post‐translationally modified peptides (RiPPs). This work establishes a unique disconnection toward cyclic heterobiaryl molecules and catalysis that is to unlock other transformations.

  • Open Access

    Synthesis of Large‐ and Medium‐Sized Heterobiaryl Atropisomeric Rings and Atropopeptides by Catalytic Intramolecular S N Ar

    by Alireza Abbasi Kejani, Paritosh Dey, Nicholas H. Stillman, Daniel M. Andrade, Michal Šimek, Martin Dračínský, Daniel Bím, Paulo H. S. Paioti

    We report the first examples of catalytic, intramolecular N‐heterocycle arylation by nucleophilic aromatic substitution (S N Ar), a general method for synthesis of highly strained macrocycles and medium‐sized heterobiaryl atropisomeric rings. Key to the approach is the ability to generate a strong base catalytically, as the desired cyclizations can be problematic under non‐catalytic conditions. Substitution reactions catalyzed by Brønsted bases often suffer from poor turnover because leaving groups are poorly basic. We put forth a process in which base regeneration does not depend on p K a considerations, but on reaction of a fluoride catalyst (Lewis base) with an organosilane (base‐embedding electrophile). Our protocol is amenable to an unprecedented broad range of heterocycles and highly functionalized and sterically hindered fluoroarenes. Despite ring strain, direct formation of C─N stereogenic axis can be carried out with linear substrates unbiased for cyclization and with tryptophan‐containing peptides. We provide synthesis of drug‐like cyclic and atropisomeric molecules which are elusive in medicinal chemistry screenings, as well as a direct macrocyclization route toward stereochemically and structurally diverse atropopeptides, molecules inspired by bioactive and naturally occurring ribosomally synthesized post‐translationally modified peptides (RiPPs). This work establishes a unique disconnection toward cyclic heterobiaryl molecules and catalysis that is to unlock other transformations.


  • Foldamers rescue synucleinopathy phenotypes in multiple in vitro and in vivo models

    by Ryan A. Dohoney, L. Palanikumar, Emily Oldani, Charles Zuwu Baysah, Johnson A. Joseph, David Polanco, Paula Santos-Otte, Nicholas H. Stillman, Peter Corcoran, Tyler D. Ball, et al.

    Synucleinopathies is an umbrella term for multiple neurological disorders, including Parkinson’s disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). A central pathological hallmark of synucleinopathies is the aggregation of α-synuclein (αS, a neuronal protein) and its prion-like spread. Therefore, inhibition of αS aggregation and spread is considered a viable therapeutic approach for the treatment of synucleinopathies. Foldamers are synthetic ligands that mimic the secondary structure of proteins. Using an oligoquinoline (OQ) scaffold–based foldamer approach, we have previously identified a foldamer (SK-129) that potently inhibits αS aggregation. Here, using a wide range of biophysical, cellular, and in vivo methods, we showed that SK-129 rescued synucleinopathy phenotypes in cellular, Caenorhabditis elegans , and human induced pluripotent stem cell (iPSC)–derived neuron models. SK-129 specifically bound to neurotoxic αS oligomers with ~6-fold higher affinity ( K d = 221 ± 29 nM) than to physiological αS monomer, validating αS oligomers as a therapeutic target. Furthermore, SK-129 efficiently crossed the blood-brain barrier (BBB) and exhibited favorable pharmaceutical properties in mice. Treatment with SK-129 prevented brain histopathology and increased survival in a mouse model expressing human A53T mutant αS without showing any apparent cytotoxicity. SK-129 inhibited αS aggregation mediated by exosomes derived from C. elegans or patients with PD in HEK293T reporter cells. SK-129 completely inhibited the coaggregation of αS-tau, a pathological biomarker for LBD in both cellular and mouse models. Overall, we report a potent foldamer with therapeutic potential for PD and LBD.


  • A Brain-Penetrating Foldamer Rescues Aβ Aggregation-Associated Alzheimer’s Disease Phenotypes in In Vivo Models

    by Charles Zuwu Baysah, Ryan A. Dohoney, L. Palanikumar, Nicholas H. Stillman, Alexandra L. Penney, Andres D. Sola, Daniel A. Paredes, Mazin Magzoub, Sunil Kumar

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the leading cause of dementia, affecting nearly 55 million people across the world. One of the central pathological factors associated with AD is the aggregation of Aβ42, a peptide product cleaved through pathological processes in AD. Under pathological conditions, Aβ42 aggregates into insoluble plaques in the brain and impairs the function of neurons, which contributes to the cognitive decline associated with AD. Therefore, the modulation of Aβ42 aggregation is considered a potential therapeutic intervention for AD. Using an Oligoquinoline-based foldamer library, we have identified a potent foldamer antagonist (SK-131) of Aβ42 aggregation. SK-131 inhibits the aggregation by inducing a α-helical structure in monomeric Aβ42. Here, we demonstrated that SK-131 rescues Aβ42 aggregation-associated phenotypes in AD cellular and multiple Caenorhabditis elegans AD models, including intracellular inhibition of Aβ42 aggregation, rescue of behavioral deficits, and attenuation of reactive oxygen species. It efficiently crosses the blood-brain barrier and demonstrates favorable pharmaceutical properties. It also potently inhibits Zn2+-mediated Aβ42 aggregation by potentially displacing Zn2+ from Aβ42. In summary, we have identified a potent brain-penetrating foldamer that efficiently rescues AD phenotypes in in vivo models. Unlike most of the therapeutic approaches that target Aβ aggregates, we have identified and validated a novel therapeutic pathway by inducing structural change in Aβ and rescuing AD phenotypes in in vivo models. This study will further aid in the quest to identify lead therapeutics to slow or stop the progression of AD.


  • Inhibition of Phosphorylated Alpha-Synuclein Aggregation by Synthetic Protein Mimetics and Foldamers

    by Emily G. Oldani, Nicholas H. Stillman, Ryan A. Dohoney, Charles Zuwu Baysah, Sunil Kumar

    The formation of Lewy bodies (LB) is a pathological hallmark for synucleinopathies, which is an umbrella term for many diseases, including Parkinson's disease, Lewy body dementia, and multiple system atrophy. One of the main components of LB is the aggregates of phosphorylated modification of α-Synuclein at residue 129 (αS-129), a neuronal protein expressed in the dopaminergic neurons in the brain. There are equivocal results about the role of αS-129, suggesting its involvement in both potentiating pathology and a functional role to rescue pathology. Regardless, a potential therapeutic strategy for LB-based pathologies could be the identification of inhibitors of both αS and αS-129 aggregation. However, to the best of our knowledge, there are no reports of ligands that can potently inhibit the aggregation of αS-129. Our group has recently identified potent antagonists of αS aggregation based on the oligopyridylamide (synthetic protein mimetics) and oligoquinoline (foldamers) scaffolds. Both ligands were potent antagonists of αS aggregation-mediated disease phenotypes in various PD models. Here, we tested both ligands against αS-129 aggregation and the coaggregation of αS and αS-129 (αS/αS-129). Both ligands were potent antagonists of αS-129 aggregation and coaggregation of αS/αS-129 in biophysical and cellular models of PD. Both ligands rescued cell toxicity mediated by the coaggregation of αS/αS-129. To the best of our knowledge, these are the first ligands that potently inhibit the major component of LB. This finding will aid in the development of therapeutic insights into aggregation-related synucleinopathies.


  • Open Access

    Protein mimetic 2D FAST rescues alpha synuclein aggregation mediated early and post disease Parkinson’s phenotypes

    by Nicholas H. Stillman, Johnson A. Joseph, Jemil Ahmed, Charles Zuwu Baysah, Ryan A. Dohoney, Tyler D. Ball, Alexandra G. Thomas, Tessa C. Fitch, Courtney M. Donnelly, Sunil Kumar

    Abberent protein-protein interactions potentiate many diseases and one example is the toxic, self-assembly of α-Synuclein in the dopaminergic neurons of patients with Parkinson’s disease; therefore, a potential therapeutic strategy is the small molecule modulation of α-Synuclein aggregation. In this work, we develop an Oligopyridylamide based 2-dimensional Fragment-Assisted Structure-based Technique to identify antagonists of α-Synuclein aggregation. The technique utilizes a fragment-based screening of an extensive array of non-proteinogenic side chains in Oligopyridylamides, leading to the identification of NS132 as an antagonist of the multiple facets of α-Synuclein aggregation. We further identify a more cell permeable analog (NS163) without sacrificing activity. Oligopyridylamides rescue α-Synuclein aggregation mediated Parkinson’s disease phenotypes in dopaminergic neurons in early and post disease Caenorhabditis elegans models. We forsee tremendous potential in our technique to identify lead therapeutics for Parkinson’s disease and other diseases as it is expandable to other oligoamide scaffolds and a larger array of side chains.